Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia

• Status: Recruiting
• Trial end date: 2021-09-15
• Target enrollment: 0
• Participant gender: All

Summary

The investigator's goal in this study is to determine the clinical efficacy and safety of continuous infusion in comparison with standard intermittent infusion.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: October 6 University
• Collaborators: Beni-Suef University; Critical Care Department,Cairo University Hospitals
• Treatments: Linezolid

Criteria

Inclusion Criteria:

• Patients admitted to ICUs diagnosed as HAP or VAP

• Chest X-ray/ computed tomography showing new or progressive infiltrate.

• New onset of purulent sputum or change in sputum character.

• Body temperature greater than 38 ℃ or less than 35.5℃.

• White blood cell counts greater than 10000 /mm3 or less than 4000 /mm3.

• Significant quantitative pathogen cultures from respiratory secretions.

Exclusion Criteria:

• Age <18 years, Pregnancy, Lactation

• Previous known allergic reaction to linezolid

• Creatinine Clearance (CrCl) <10 mL/min, calculated according to the Cockcroft-Gault formula

• Thrombocytopenia (platelet count less than 80,000/mm3)

• Severe hepatic failure (Child-Pugh C)

• Concomitant treatment with other drugs that can potentially interfere with Linezolid (i.e., macrolides, serotonin modulators, omeprazole)

• Acute DIC score > 4 points or hematological disorder

• Concurrent drug-associated Thrombocytopenia